期刊文献+

高血压的治疗进展:新药物、新技术与血压管理 被引量:3

Hypertension treatment:new drugs,new technique and blood pressure management
原文传递
导出
摘要 控制高血压是降低心脑血管事件的关键。现阶段我国高血压的控制率仍很低,原因为药物的不合理使用、患者对高血压的危害及防治意识不足、治疗依从性不佳及难治性高血压等。针对以上问题,本文围绕如何合理使用降压药物和管理血压、新型降压药物的研发及高血压治疗器械与操作作一综述,以期指导临床实践,提高我国的高血压控制率。 Summary Effective control of hypertension is the key to reduce cardiovascular and cerebrovascular events. At present, the control rate of hypertension remains low in China. The reasons for this include irrational use o~ drugs, the patients lack awareness of the dangers and the necessity for treatment, poor treatment compliance and refractory hypertension. Here, we review the rational use of existing antihypertensive drugs, rational management of blood pressure, the development of new antihypertensive drugs and hypertension treatment equipment and approaches in this article. We hope to provide a guide for clinicians and improve the control rate of hypertension.
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2013年第10期723-725,共3页 Journal of Clinical Cardiology
关键词 高血压 血压管理 新药物 新技术 hypertension blood pressure managements new drug new technique
  • 相关文献

参考文献6

  • 1MANCIA G, FAGARD R, NARKIEWICZ K, et al. 2013ESH/ESC Guidelines for the management of arterial hy-pertension: the Task Force for the management of arterialhypertension of the European Society of Hypertension(ESH) and of the European Society of Cardiology (ESC)[J]. J Hypertens,2013,31 : 1281 —1357.
  • 2LAURENT S, SCHLAICH M,ESLER M New drugs,procedures, and devices for hypertension[J]. Lancet,2012,380:591-600.
  • 3CHEN X, QIU Z H, YANG S J, et al Effectiveness andsafety of a therapeutic vaccine against AT 1 receptor in h:pertensive animals[J]. Hypertension,2013,61 :408—416.
  • 4BRIASOULIS A, BAKRIS G. The future of inter-ventional management of hypertension: threats andopportunities[J]. Curr Vase Pharmacol,2013,[Epubahead of print].
  • 5ESLER M D,KRUM H,SCHLAICH M,et al. Sym-plicity HTN-2 Investigators. Renal sympathetic denerva-tion for treatment of drug-resistant hypertension : one-year results from the Symplicity HTN-2 randomized,controlled trial[J]. Circulation.20l2,126:2976 -2982.
  • 6Symplicity HTN-2 Investigators, ESLER M D, KRUMH, SOBOTKA P A, et al. Renal sympathetic denerva-tion in patients with treatment-resistant hypertension(The Symplicity HTN-2 Trial) : a randomised controlledtrial[J]. Lancet,2010,376: 1903 —1909.

同被引文献35

引证文献3

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部